Invasive fungal infections and antifungal therapies in solid organ transplant recipients

Transplant International

Volumn 20, Issue 12, 2007, Pages 993-1015

  Gabardi, Steven ^a,b   Kubiak, David W ^a   Chandraker, Anil K ^a,b   Tullius, Stefan G ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antifungal agents; Infectious complications; Invasive fungal infections; Solid organ transplantation

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CALCINEURIN INHIBITOR; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; METHYLPREDNISOLONE; MICAFUNGIN; MYCOPHENOLIC ACID; NYSTATIN; POSACONAZOLE; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; TERBINAFINE; VORICONAZOLE;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ANOREXIA; ASPERGILLUS; BLASTOMYCES; BLURRED VISION; BONE MARROW SUPPRESSION; CANDIDA; CARDIOTOXICITY; CHILL; CHOLESTASIS; COCCIDIOIDES; CONFUSION; CONGESTIVE HEART FAILURE; CRYPTOCOCCUS; DEEP VEIN THROMBOSIS; DIARRHEA; DIPLOPIA; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; FEVER; FUSARIUM; GRAFT RECIPIENT; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART GRAFT; HISTOPLASMA; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNE DEFICIENCY; INDIGESTION; KIDNEY GRAFT; LIVER FAILURE; LIVER GRAFT; LIVER TOXICITY; LOADING DRUG DOSE; LUNG TRANSPLANTATION; MALAISE; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; PANCREAS TRANSPLANTATION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHAEOHYPHOMYCOSIS; PHLEBITIS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; QT PROLONGATION; RASH; REVIEW; RIGOR; RISK FACTOR; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SURGICAL TECHNIQUE; SWELLING; TACHYPNEA; THROMBOPHLEBITIS; VIRUS INFECTION; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

ANTIFUNGAL AGENTS; HUMANS; MYCOSES; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 35748962587     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00511.x     Document Type: Review

References (166)

1. Fungal infections. Am J Transplant 2004 4 (Suppl. 10 110.
2. Marik PE. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 2006 7 : 297.
3. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003 17 : 113, viii.
4. Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001 3 : 203.
5. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999 1 : 229.
6. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001 33 : 1692.
7. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002 73 : 63.
8. Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005 41 : 52.
9. Patterson TF. Approaches to fungal diagnosis in transplantation. Transpl Infect Dis 1999 1 : 262.
10. Chamilos G, Kontoyiannis DP. Defining the diagnosis of invasive aspergillosis. Med Mycol 2006 44 (Suppl. 163.
11. Chryssanthou E, Klingspor L, Tollemar J, et al. PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients. Mycoses 1999 42 : 239.
12. Dictar MO, Maiolo E, Alexander B, Jacob N, Veron MT. Mycoses in the transplanted patient. Med Mycol 2000 38 (Suppl. 1 251.
13. Shao PL, Huang LM, Hsueh PR. Invasive fungal infection-laboratory diagnosis and antifungal treatment. J Microbiol Immunol Infect 2006 39 : 178.
14. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006 55 : 809.
15. Kauffman CA. Fungal infections. Proc Am Thorac Soc 2006 3 : 35.
16. Hellinger WC, Bonatti H, Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005 11 : 656.
17. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001 3 : 161.
18. Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis 2003 37 (Suppl. 3 S281.
19. Anaissie EJ, Stratton SL, Dignani MC, et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002 35 : E86.
20. Anaissie E, Bodey GP. Nosocomial fungal infections. Old problems and new challenges. Infect Dis Clin North Am 1989 3 : 867.
21. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996 9 : 499.
22. Kahan BD. Introduction to solid-organ transplantation. In : Bowden RALP, Paya CV, eds. Transplant Infections. Transplant Infections. New York : Lippincott-Raven, 1998 : pp. 13 19.
23. Limaye AP, Connolly PA, Sagar M, et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med 2000 343 : 1163.
24. Ooi BS, Chen BT, Lim CH, Khoo OT, Chan DT. Survival of a patient transplanted with a kidney infected with Cryptococcus neoformans. Transplantation 1971 11 : 428.
25. Keating MR, Guerrero MA, Daly RC, Walker RC, Davies SF. Transmission of invasive aspergillosis from a subclinically infected donor to three different organ transplant recipients. Chest 1996 109 : 1119.
26. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994 170 : 644.
27. Hibberd PL, Rubin RH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 1994 19 (Suppl. 1 S33.
28. Singh N, Gayowski T, Wagener MM, Marino IR. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996 61 : 402.
29. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997 64 : 716.
30. Dockrell DH, Mendez JC, Jones M, et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation 1999 67 : 399.
31. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997 10 : 86.
32. Kaufman DB, Leventhal JR, Koffron A, et al. Simultaneous pancreas-kidney transplantation in the mycophenolate mofetil/tacrolimus era: evolution from induction therapy with bladder drainage to noninduction therapy with enteric drainage. Surgery 2000 128 : 726.
33. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005 18 : 44.
34. Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 2004 4 : 636.
35. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002 4 : 195.
36. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003 22 : 258.
37. Perfect JR, Casadevall A. Cryptococcosis. Infect Dis Clin North Am 2002 16 : 837, v-vi.
38. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001 7 : 375.
39. Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005 80 : 1033.
40. Jabbour N, Reyes J, Kusne S, Martin M, Fung J. Cryptococcal meningitis after liver transplantation. Transplantation 1996 61 : 146.
41. John GT, Mathew M, Snehalatha E, et al. Cryptococcosis in renal allograft recipients. Transplantation 1994 58 : 855.
42. Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002 2 : 575.
43. Bradsher RW, Chapman SW, Pappas PG. Blastomycosis. Infect Dis Clin North Am 2003 17 : 21, vii.
44. Serody JS, Mill MR, Detterbeck FC, Harris DT, Cohen MS. Blastomycosis in transplant recipients: report of a case and review. Clin Infect Dis 1993 16 : 54.
45. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005 41 : 1217.
46. Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001 33 : 1536.
47. Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med 1982 142 : 489.
48. Wheat LJ, Kauffman CA. Histo plasmosis. Infect Dis Clin North Am 2003 17 : 1, vii.
49. Freifeld AG, Iwen PC, Lesiak BL, Gilroy RK, Stevens RB, Kalil AC. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis 2005 7 : 109.
50. Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001 32 : 1237.
51. Fang CT, Chang SC, Tang IL, et al. Fusarium solani fungemia in a bone marrow transplant recipient. J Formos Med Assoc 1997 96 : 129.
52. Garcia-Diaz JB, Baumgarten K. Phaeohyphomycotic infections in solid organ transplant patients. Semin Respir Infect 2002 17 : 303.
53. Pereiro M Jr., Pereiro Ferreiros MM, De Hoog GS, Toribio J. Cutaneous infection caused by Alternaria in patients receiving tacrolimus. Med Mycol 2004 42 : 277.
54. Levin TP, Baty DE, Fekete T, Truant AL, Suh B. Cladophialophora bantiana brain abscess in a solid-organ transplant recipient: case report and review of the literature. J Clin Microbiol 2004 42 : 4374.
55. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003 37 : 221.
56. Clancy CJ, Wingard JR, Hong Nguyen M. Subcutaneous phaeohyphomycosis in transplant recipients: review of the literature and demonstration of in vitro synergy between antifungal agents. Med Mycol 2000 38 : 169.
57. Chua JD, Gordon SM, Banbury J, Hall GS, Procop GW. Relapsing Exophiala jeanselmei phaeohyphomycosis in a lung-transplant patient. Transpl Infect Dis 2001 3 : 235.
58. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003 16 : 607.
59. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006 6 : 2365.
60. Singh N, Gayowski T, Singh J, Yu VL. Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis 1995 20 : 617.
61. Dodds Ashley ES. Treatment options for invasive fungal infections. Pharmacotherapy 2006 26 (6 Pt 2 55S.
62. Dodds Ashley ES, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006 43 (Suppl. 1 s28.
63. Agger WA, Andes D, Burgess JW. Exophiala jeanselmei infection in a heart transplant recipient successfully treated with oral terbinafine. Clin Infect Dis 2004 38 : e112.
64. Duran MT, Del Pozo J, Yebra MT, et al. Cutaneous infection caused by Ulocladium chartarum in a heart transplant recipient: case report and review. Acta Derm Venereol 2003 83 : 218.
65. Schelenz S, Goldsmith DJ. Aspergillus endophthalmitis: an unusual complication of disseminated infection in renal transplant patients. J Infect 2003 47 : 336.
66. Sellier P, Monsuez JJ, Lacroix C, et al. Recurrent subcutaneous infection due to Scopulariopsis brevicaulis in a liver transplant recipient. Clin Infect Dis 2000 30 : 820.
67. Clark NM. Paecilomyces lilacinus infection in a heart transplant recipient and successful treatment with terbinafine. Clin Infect Dis 1999 28 : 1169.
68. Lee KH, Kim YS, Kim MS, Chung HS, Park K. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Transplant Proc 1996 28 : 1488.
69. Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis 2003 5 : 140.
70. Munoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used? Curr Opin Infect Dis 2006 19 : 365.
71. Vilchez R, Shapiro R, McCurry K, et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int 2003 16 : 336.
72. Singh N, Gayowski T, Marino IR. Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an all oral regimen. Transpl Int 1998 11 : 63.
73. Said T, Nampoory MR, Nair MP, et al. Safety of caspofungin for treating invasive nasal sinus aspergillosis in a kidney transplant recipient. Transplant Proc 2005 37 : 3038.
74. Salvalaggio PR, Bassetti M, Lorber MI, et al. Aspergillus vertebral osteomyelitis after simultaneous kidney-pancreas transplantation. Transpl Infect Dis 2003 5 : 187.
75. Forestier E, Remy V, Lesens O, et al. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole. Eur J Clin Microbiol Infect Dis 2005 24 : 347.
76. Kline SS, Buell D, Walsh T. AmBisome Used Concomitantly with Potential Nephrotoxic Agents. Atlanta, GA : American Society of Health-System Pharmacists Midyear Clinical Meeting, 1997.
77. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997 29 : 627.
78. Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006 6 : 2765.
79. Drew RH, Dodds Ashley E, Benjamin DK Jr., Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004 77 : 232.
80. Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 2006 27 (Suppl. 1 36.
81. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001 72 : 545.
82. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003 75 : 1571.
83. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999 131 : 729.
84. van Burik JA. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis 2005 18 : 479.
85. Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant 2005 24 : 2148.
86. Reents S, Goodwin SD, Singh V. Antifungal prophylaxis in immunocompromised hosts. Ann Pharmacother 1993 27 : 53.
87. Paya CV. Prevention of fungal infection in transplantation. Transpl Infect Dis 2002 4 (Suppl. 3 46.
88. Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006 6 : 386.
89. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006 Dec 6 (12 3008 16.
90. Graybill JR. Prevention of systemic mycoses in patients who are not neutropenic: should we do it? Can we do it? Braz J Infect Dis 2000 4 : 108.
91. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006 12 : 850.
92. Zeluff BJ. Fungal pneumonia in transplant recipients. Semin Respir Infect 1990 5 : 80.
93. Virgili A, Zampino MR, Mantovani L. Fungal skin infections in organ transplant recipients. Am J Clin Dermatol 2002 3 : 19.
94. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006 81 : 320.
95. Peddi VR, Hariharan S, First MR. Disseminated histoplasmosis in renal allograft recipients. Clin Transplant 1996 10 : 160.
96. Fortun J, Martin-Davila P, Sanchez MA, et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003 22 : 408.
97. Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003 76 : 1632.
98. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001 33 : 629.
99. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993 16 : 677.
100. Dummer JS, Montero CG, Griffith BP, Hardesty RL, Paradis IL, Ho M. Infections in heart-lung transplant recipients. Transplantation 1986 41 : 725.
101. Herrmann M, Weyand M, Greshake B, et al. Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 1997 95 : 814.
102. Goldstein DJ, el-Amir NG, Ashton RC Jr., et al. Fungal infections in left ventricular assist device recipients. Incidence, prophylaxis, and treatment. ASAIO J 1995 41 : 873.
103. Nurozler F, Argenziano M, Oz MC, Naka Y. Fungal left ventricular assist device endocarditis. Ann Thorac Surg 2001 71 : 614.
104. Fortun J, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002 8 : 1065.
105. Singh N, Pruett TL, Houston S, et al. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl 2006 12 : 1205.
106. Singh N, Limaye AP, Forrest G, et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 2006 44 : 445.
107. Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003 52 : 813.
108. Singh N, Keyes L, Akoad M, Cacciarelli TV. Efficacy of Antifungal Prophylaxis Targeted Towards High-risk Liver Transplant Recipients for the Prevention of Invasive Aspergillosis. Boston, MA, USA : World Transplant Congress, 2006.
109. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004 39 (Suppl. 4 S200.
110. Hagerty JA, Ortiz J, Reich D, Manzarbeitia C. Fungal infections in solid organ transplant patients. Surg Infect (Larchmt) 2003 4 : 263.
111. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis 2002 4 (Suppl. 3 24.
112. Nicod LP, Pache JC, Howarth N. Fungal infections in transplant recipients. Eur Respir J 2001 17 : 133.
113. Hadjiliadis D, Howell DN, Davis RD, et al. Anastomotic infections in lung transplant recipients. Ann Transplant 2000 5 : 13.
114. Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004 23 : 632.
115. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000 70 : 112.
116. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004 23 : 1376.
117. Lowry CM, Vargas SO, Lee JT, Fiumara K, Deykin A, Baden LR. Retrospective review of the safety or aerosolized liposomal versus conventional amphotericin B for prevention of invasive fungal infections following lung transplantation. Transpl Infect Dis 2007 9 (2 121 5.
118. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis 2005 18 : 342.
119. Lumbreras C, Fernandez I, Velosa J, Munn S, Sterioff S, Paya CV. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 1995 20 : 514.
120. Benedetti E, Gruessner AC, Troppmann C, et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg 1996 183 : 307.
121. Michalak G, Kwiatkowski A, Bieniasz M, et al. Infectious complications after simultaneous pancreas-kidney transplantation. Transplant Proc 2005 37 : 3560.
122. Berger N, Wirmsberger R, Kafka R, et al. Infectious complications following 72 consecutive enteric-drained pancreas transplants. Transpl Int 2006 19 : 549.
123. Pirsch JD, Odorico JS, D'Alessandro AM, Knechtle SJ, Becker BN, Sollinger HW. Posttransplant infection in enteric versus bladder-drained simultaneous pancreas-kidney transplant recipients. Transplantation 1998 66 : 1746.
124. Safdar N, Slattery WR, Knasinski V, et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis 2005 40 : 1413.
125. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995 9 : 1045.
126. Singh N, Heitman J. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation 2004 77 : 795.
127. Brayman KL, Stephanian E, Matas AJ, et al. Analysis of infectious complications occurring after solid-organ transplantation. Arch Surg 1992 127 : 38 discussion 47.
128. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH Jr. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis 1983 148 : 230.
129. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004 38 : 161.
130. Speich R, Dutly A, Naef R, Russi EW, Weder W, Boehler A. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly 2002 132 : 455.
131. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomised controlled trial. BMJ 2001 322 : 579.
132. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003 36 : 943.
133. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000 30 : 696.
134. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000 30 : 710.
135. Chapman SW, Bradsher RW Jr., Campbell GD Jr., Pappas PG, Kauffman CA. Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000 30 : 679.
136. Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000 30 : 658.
137. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 2000 30 : 688.
138. Durand-Joly I, Alfandari S, Benchikh Z, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol 2003 41 : 4898.
139. Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin Infect Dis 2003 37 : 311.
140. Sagnelli C, Fumagalli L, Prigitano A, Baccari P, Magnani P, Lazzarin A. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. J Antimicrob Chemother 2006 57 : 796.
141. Herbrecht R, Kessler R, Kravanja C, Meyer MH, Waller J, Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004 23 : 1451.
142. Caligiorne RB, Resende MA, Melillo PH, Peluso CP, Carmo FH, Azevedo V. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med Mycol 1999 37 : 405.
143. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001 150 : 101.
144. Al-Abdely HM, Najvar L, Bocanegra R, et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum (''Ramichloridium mackenziei''). Antimicrob Agents Chemother 2000 44 : 1159.
145. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006 42 : e61.
146. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001 20 : 460.
147. Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Arch Intern Med 1996 156 : 337.
148. Saad AH, Depestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006 26 : 1730.
149. Gubbins PO, Amsden JR. Chapter 10. Antifungal Agents, 2nd edn. Totowa, NJ : Humana Press, 2005. (V SG, ed. Drug Interactions in Infectious Diseases).
150. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004 6 : 110.
151. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004 34 : 13.
152. Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005 45 : 954.
153. Tiao GM, Martin J, Weber FL, Cohen RM, Hanto DW. Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. Clin Transplant 1999 13 (1 Pt 1 62.
154. Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation 2002 74 : 1477.
155. Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998 64 : 363.
156. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999 85 : 29.
157. Linthoudt H, Van Raemdonck D, Lerut T, Demedts M, Verleden G. The association of itraconazole and methylprednisolone may give rise to important steroid-related side effects. J Heart Lung Transplant 1996 15 : 1165.
158. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000 68 : 487.
159. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000 56 : 57.
160. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001 51 : 443.
161. Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998 46 : 271.
162. Raad II., Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006 42 : 1726.
163. Sansome-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007 27 (6 825 34.
164. Ghahramani PPL, Klienermans D, Nichols DJ. The pharmacokinetics of voriconazole and its effect on prednisolone disposition. Interscience Conference on Antimicrobial Agents and Chemotherapy (40th), Toronto, ON, Canada, 2000.
165. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002 71 : 226.
166. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006 12 : 552.